Skip to main content

Market Overview

FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease

  • Under Priority Review status, the FDA has accepted Incyte Corporation's (NASDAQ: INCY) marketing application for review seeking approval for ruxolitinib cream.
  • Ruxolitinib is a selective JAK1/JAK2 inhibitor as a treatment for atopic dermatitis, a type of eczema characterized by inflammation and intense itch.
  • The company has submitted a Priority Review Voucher (PRV) along with the application for ruxolitinib cream. The use of the PRV shortens the review period by four months. The agency's action date is June 21.
  • Price Action: INCY increased 0.55% at $82 on last check Friday.

Related Articles (INCY)

View Comments and Join the Discussion!

Posted-In: atopic dermatitisBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at